Kamau Therapeutics

Kamau Therapeutics is a clinical-stage gene correction company dedicated to transforming the lives of patients with devastating genetic diseases through best-in-class, curative stem-cell therapies. Kamau stands apart through the unique capabilities of its next-generation gene correction platform that directly corrects genetic mutations with unprecedented precision: removing the pathologic mutation and replacing it with the healthy version. The company's platform technology is based on the pioneering research of company co-founder Dr. Matthew Porteus, MD, PhD. Kamau's lead clinical program, nula-cel, is a hematopoietic stem-cell therapy in development for sickle cell disease that precisely corrects the mutation in the beta-globin gene.